MNPR Stock Summary and Trading Ideas (Monopar Therapeutics | NASDAQ:MNPR)

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of?Validive?for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin?for the treatment?of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Monopar Therapeutics trades on the NASDAQ stock market under the symbol MNPR.

As of February 14, 2025, MNPR stock price declined to $43.10 with 55,414 million shares trading.

MNPR has a beta of 2.94, meaning it tends to be more sensitive to market movements. MNPR has a correlation of 0.03 to the broad based SPY ETF.

MNPR has a market cap of $262.84 million. This is considered a Small Cap stock.

In the last 3 years, MNPR traded as high as $54.30 and as low as $1.37.

The top ETF exchange traded funds that MNPR belongs to (by Net Assets): VXF.

MNPR has outperformed the market in the last year with a price return of +2511.3% while the SPY ETF gained +24.8%. MNPR has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +124.1% and +1.4%, respectively, while the SPY returned +2.4% and +0.8%, respectively.

MNPR support price is $39.88 and resistance is $49.48 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MNPR shares will trade within this expected range on the day.